Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Beijing Friendship Hospital
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05775705CT.gov L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Dep (this asset) | Beijing Friendship Hospital | P3 | B · 60 |
| Rituximab | Jennifer Amengual | P2 | BB |
| Bortezomib | Massachusetts General Hospital | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Baltaleucel-T | Cell Medica Ltd | P2 | CCC |
| Tabelecleucel | Pierre Fabre Medicament | P2 | CCC |
| Tucidinostat | Huiqiang Huang | P2 | CCC |
| Star0602 | Marengo Therapeutics, Inc. | P1/2 | CCC |
| Brentuximab Vedotin | Northwestern University | P1/2 | CCC |
+8 more in the Epstein-Barr Virus Infection cohort
Other indications for L-Dep
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophagocytic Syndrome | — | P3 | B · 60 |
| Lymphoma | — | P3 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Dep in Epstein-Barr Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-dep-epstein-barr-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →